TickerFacts.

Caris Life Sciences, Inc. (CAI): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

$67.73M
Year ended 2025-12-31
$174.03M
Trailing 12 months to 2026-06-30
2023-12-31: -$270.55M2024-12-31: -$208.21M2025-12-31: $67.73M$67.73M
2023-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31$67.73Mn/m2026-03-03, From 2025-01-01
2024-12-31-$208.21Mn/m2026-03-03, From 2024-01-01
2023-12-31-$270.55Mn/a2026-03-03, From 2023-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Caris Life Sciences, Inc. (CAI)2025-12-31$67.73Mn/m
Guardant Health, Inc. (GH)2025-12-31-$397.51Mn/m
Veracyte, Inc. (VCYT)2025-12-31$79.19M+100.0%
CareDx, Inc. (CDNA)2025-12-31-$15.76Mn/m
Castle Biosciences Inc (CSTL)2025-12-31-$2.04Mn/m
RadNet, Inc. (RDNT)2025-12-31$198.09M-13.8%
Fulgent Genetics, Inc. (FLGT)2025-12-31-$66.97Mn/m
BillionToOne, Inc. (BLLN)2025-12-31$22.92Mn/m
Natera, Inc. (NTRA)2025-12-31-$268.15Mn/m

Compare CAI, GH, VCYT, CDNA side by side · Screen every company in Services-Medical Laboratories ↗